OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
Manaf AlQahtani, Nitya Kumar, Dhuha Aljawder, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Manaf AlQahtani, Nitya Kumar, Dhuha Aljawder, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Viravarn Luvira, William HK Schilling, Podjanee Jittamala, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 16
Viravarn Luvira, William HK Schilling, Podjanee Jittamala, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 16
Favipiravir for treating COVID-19
Pritish John Korula, Hanna Alexander, Jisha Sara John, et al.
Cochrane library (2024) Vol. 2024, Iss. 2
Open Access | Times Cited: 10
Pritish John Korula, Hanna Alexander, Jisha Sara John, et al.
Cochrane library (2024) Vol. 2024, Iss. 2
Open Access | Times Cited: 10
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand
Pinyo Rattanaumpawan, Supunnee Jirajariyavej, Kanokorn Lerdlamyong, et al.
Antibiotics (2022) Vol. 11, Iss. 6, pp. 805-805
Open Access | Times Cited: 28
Pinyo Rattanaumpawan, Supunnee Jirajariyavej, Kanokorn Lerdlamyong, et al.
Antibiotics (2022) Vol. 11, Iss. 6, pp. 805-805
Open Access | Times Cited: 28
Drugs for COVID-19: An Update
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8562-8562
Open Access | Times Cited: 23
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8562-8562
Open Access | Times Cited: 23
Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
Atefeh Vaezi, Mehrzad Salmasi, Forogh Soltaninejad, et al.
Advances in respiratory medicine (2023) Vol. 91, Iss. 1, pp. 18-25
Open Access | Times Cited: 10
Atefeh Vaezi, Mehrzad Salmasi, Forogh Soltaninejad, et al.
Advances in respiratory medicine (2023) Vol. 91, Iss. 1, pp. 18-25
Open Access | Times Cited: 10
Synthesis and Antiviral Properties against SARS-CoV-2 of Epoxybenzooxocino[4,3-b]Pyridine Derivatives
Alena L. Stalinskaya, Nadezhda V. Martynenko, Zarina Shulgau, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3701-3701
Open Access | Times Cited: 15
Alena L. Stalinskaya, Nadezhda V. Martynenko, Zarina Shulgau, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3701-3701
Open Access | Times Cited: 15
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 12, pp. 1299-1311
Closed Access | Times Cited: 15
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 12, pp. 1299-1311
Closed Access | Times Cited: 15
Favipiravir does not improve viral clearance in mild to moderate COVID-19 – A systematic review and meta-analysis of randomized controlled trials
Muh. Akbar Bahar, Ikhwan Yuda Kusuma, Ádám Visnyovszki, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29808-e29808
Open Access | Times Cited: 1
Muh. Akbar Bahar, Ikhwan Yuda Kusuma, Ádám Visnyovszki, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29808-e29808
Open Access | Times Cited: 1
Treating COVID-19: Targeting the Host Response, Not the Virus
David S. Fedson
Life (2023) Vol. 13, Iss. 3, pp. 712-712
Open Access | Times Cited: 4
David S. Fedson
Life (2023) Vol. 13, Iss. 3, pp. 712-712
Open Access | Times Cited: 4
Molecular insights into the sensing function of an oxidized graphene flake for the adsorption of Avigan antiviral drug
Renzon Daniel Cosme Pecho, Narjes Hajali, Ruben Dario Tapia-Silguera, et al.
Computational and Theoretical Chemistry (2023) Vol. 1227, pp. 114240-114240
Closed Access | Times Cited: 3
Renzon Daniel Cosme Pecho, Narjes Hajali, Ruben Dario Tapia-Silguera, et al.
Computational and Theoretical Chemistry (2023) Vol. 1227, pp. 114240-114240
Closed Access | Times Cited: 3
Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked
M. Zh. Zhurinov, A. F. Miftakhova, Viktoriya Keyer, et al.
Molecules (2023) Vol. 28, Iss. 16, pp. 6142-6142
Open Access | Times Cited: 3
M. Zh. Zhurinov, A. F. Miftakhova, Viktoriya Keyer, et al.
Molecules (2023) Vol. 28, Iss. 16, pp. 6142-6142
Open Access | Times Cited: 3
Quantitative Analysis of Favipiravir by HPLC: Development and Validation
Moammal Qurt, Rania Eshtayyeh, Hani Naseef, et al.
International Journal of Analytical Chemistry (2023) Vol. 2023, pp. 1-9
Open Access | Times Cited: 3
Moammal Qurt, Rania Eshtayyeh, Hani Naseef, et al.
International Journal of Analytical Chemistry (2023) Vol. 2023, pp. 1-9
Open Access | Times Cited: 3
Three-step process for the synthesis of favipiravir
Swarnayu Banik, D.R. Adarsh, B. V. Subba Reddy
Results in Chemistry (2023) Vol. 5, pp. 100895-100895
Open Access | Times Cited: 2
Swarnayu Banik, D.R. Adarsh, B. V. Subba Reddy
Results in Chemistry (2023) Vol. 5, pp. 100895-100895
Open Access | Times Cited: 2
Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals
Kamaleldin B. Said, Ahmed Alsolami, Fayez Saud Alreshidi, et al.
Journal of Multidisciplinary Healthcare (2023) Vol. Volume 16, pp. 1215-1229
Open Access | Times Cited: 2
Kamaleldin B. Said, Ahmed Alsolami, Fayez Saud Alreshidi, et al.
Journal of Multidisciplinary Healthcare (2023) Vol. Volume 16, pp. 1215-1229
Open Access | Times Cited: 2
COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
Serap Şimşek Yavuz
Infectious Diseases and Clinical Microbiology (2023) Vol. 5, Iss. 3, pp. 165-187
Open Access | Times Cited: 2
Serap Şimşek Yavuz
Infectious Diseases and Clinical Microbiology (2023) Vol. 5, Iss. 3, pp. 165-187
Open Access | Times Cited: 2
Advanced Pedestrian State Sensing Method for Automated Patrol Vehicle Based on Multi-Sensor Fusion
Pangwei Wang, Cheng Liu, Yunfeng Wang, et al.
Sensors (2022) Vol. 22, Iss. 13, pp. 4807-4807
Open Access | Times Cited: 4
Pangwei Wang, Cheng Liu, Yunfeng Wang, et al.
Sensors (2022) Vol. 22, Iss. 13, pp. 4807-4807
Open Access | Times Cited: 4
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial
Viravarn Luvira, William HK Schilling, Podjanee Jittamala, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Viravarn Luvira, William HK Schilling, Podjanee Jittamala, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Favipiravir for the Treatment of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Aiman Naveed, Huzaifa Ahmad Cheema, Abia Shahid, et al.
American Journal of Therapeutics (2024)
Closed Access
Aiman Naveed, Huzaifa Ahmad Cheema, Abia Shahid, et al.
American Journal of Therapeutics (2024)
Closed Access
Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
Juan Pablo Horcajada, Rebeca Aldonza, Mónica Real, et al.
Pneumonia (2024) Vol. 16, Iss. 1
Open Access
Juan Pablo Horcajada, Rebeca Aldonza, Mónica Real, et al.
Pneumonia (2024) Vol. 16, Iss. 1
Open Access
ЕТІОЛОГІЧНІ, ЕПІДЕМІОЛОГІЧНІ ТА КЛІНІЧНІ АСПЕКТИ ГАРЯЧКИ ЗАХІДНОГО НІЛУ
В. С. Копча
Інфекційні хвороби (2024), Iss. 4, pp. 51-63
Closed Access
В. С. Копча
Інфекційні хвороби (2024), Iss. 4, pp. 51-63
Closed Access
PIONEER trial: favipiravir to treat moderate COVID-19
Sarah Shalhoub
The Lancet Respiratory Medicine (2022) Vol. 11, Iss. 5, pp. 392-393
Open Access | Times Cited: 3
Sarah Shalhoub
The Lancet Respiratory Medicine (2022) Vol. 11, Iss. 5, pp. 392-393
Open Access | Times Cited: 3
Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic
Iqra Mir, Sania Aamir, Syed Rizwan Hussain Shah, et al.
Osong Public Health and Research Perspectives (2022) Vol. 13, Iss. 2, pp. 84-100
Open Access | Times Cited: 1
Iqra Mir, Sania Aamir, Syed Rizwan Hussain Shah, et al.
Osong Public Health and Research Perspectives (2022) Vol. 13, Iss. 2, pp. 84-100
Open Access | Times Cited: 1
Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
British Journal of Clinical Pharmacology (2023) Vol. 89, Iss. 4, pp. 1282-1290
Open Access
Behnam Amani, Bahman Amani
British Journal of Clinical Pharmacology (2023) Vol. 89, Iss. 4, pp. 1282-1290
Open Access
Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
Juan Pablo Horcajada, Rebeca Aldonza, Mónica Real, et al.
Research Square (Research Square) (2023)
Open Access
Juan Pablo Horcajada, Rebeca Aldonza, Mónica Real, et al.
Research Square (Research Square) (2023)
Open Access
Drug Repurposing for COVID-19: Current Status of Potential Therapeutics
Pravalika Avirineni, Sudheer K. Dundigalla, Satyanarayana S. V. Padi
Journal of Advances in Medical and Pharmaceutical Sciences (2023) Vol. 25, Iss. 11, pp. 40-60
Open Access
Pravalika Avirineni, Sudheer K. Dundigalla, Satyanarayana S. V. Padi
Journal of Advances in Medical and Pharmaceutical Sciences (2023) Vol. 25, Iss. 11, pp. 40-60
Open Access
